You are invited to a Presentation on:

Treating the Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis

Presented by
Ronald Dasher, PHARM
Rxperts

Date & Location
Saturday, April, 08, 2017
12:00 PM Eastern
At Hilton Baltimore BWI Airport
1739 West Nursery Road
Linthicum Heights, Maryland 21090

Program Objectives
• Understand the symptoms, diagnosis, and impact of the hallucinations and delusions associated with Parkinson’s disease psychosis (PDP)
• Explore the proposed mechanism of action of NUPLAZID (pimavanserin)
• Discuss the efficacy, safety, and administration of NUPLAZID for the treatment of hallucinations and delusions associated with PDP

RSVP Information
Please call Tarah Bowen at 631-807-3615 or email tbowen@acadia-pharm.com
Please refer to Meeting ID number: ACA0002602

Important Safety Information and Indication for NUPLAZID™ (pimavanserin) tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson’s disease psychosis.
**QT Interval Prolongation:** NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

**Adverse Reactions:** The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

**Drug Interactions:**
Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half.
Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

**Renal Impairment:** No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

**Hepatic Impairment:** Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

**Pediatric Use:** Safety and efficacy have not been established in pediatric patients.

**Dosage and Administration:** Recommended dose: 34 mg per day, taken orally as two 17 mg tablets once daily, without titration.

**INDICATIONS AND USAGE**
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Please click here to see Full Prescribing Information.

www.NUPLAZID.com